Literature DB >> 26723972

Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.

Ming Chen1, Shi-hao Zheng2, Yi Liu1, Jin Shi1, Song-tao Qi3.   

Abstract

Periostin (POSTN) is an extracellular matrix protein (ECM) critical for epithelial-mesenchymal transitions (EMT) in several kinds of tumor cells. Previous studies have indicated that EMT exists in craniopharyngioma (CP), and expression of POSTN is a significant factor in the prognosis of CP. However, it has never been explored whether POSTN exists in CP, or how it activates CP's EMT. The expression of POSTN was examined in adamantinomatous craniopharyngioma (ACP) primary cells and tissues by immunohistochemistry, PCR and Western blot, respectively. The effects and mechanisms of POSTN on ACP cells' EMT were also analyzed. It was found that POSTN expression increased in ACP-associated fibroblasts. Overexpressed POSTN significantly elevated the EMT of ACP cells by regulating the expression of associated genes. More importantly, our further study revealed that the upregulated POSTN activated Akt signaling pathway to regulate the EMT. This study showed that POSTN is responsible for the EMT of ACP cells, and POSTN might be a potential molecular therapeutic target for ACP treatment in future.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Craniopharyngioma; Epithelial–mesenchymal transition; Periostin; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26723972     DOI: 10.1016/j.jns.2015.11.042

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Beyond epithelial-to-mesenchymal transition: Common suppression of differentiation programs underlies epithelial barrier dysfunction in mild, moderate, and severe asthma.

Authors:  L F Loffredo; H Abdala-Valencia; K R Anekalla; L Cuervo-Pardo; C J Gottardi; S Berdnikovs
Journal:  Allergy       Date:  2017-07-06       Impact factor: 13.146

2.  Prediction of calcification tendency in pediatric cystic adamantinomatous craniopharyngioma by using inflammatory markers, hormone markers, and radiological appearances.

Authors:  Ming Chen; Zhang Zhang; Min Yang; Shi-Ting Li
Journal:  Childs Nerv Syst       Date:  2019-05-07       Impact factor: 1.475

3.  The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study.

Authors:  Ming Chen; Shi-Hao Zheng; Min Yang; Zhi-Hua Chen; Shi-Ting Li
Journal:  J Neurooncol       Date:  2018-01-31       Impact factor: 4.130

4.  TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.

Authors:  Yi Liu; Chao-Hu Wang; Dan-Ling Li; Shi-Chao Zhang; Yu-Ping Peng; Jun-Xiang Peng; Ye Song; Song-Tao Qi; Jun Pan
Journal:  Oncotarget       Date:  2016-08-02

5.  Identification and Characterization of TF-lncRNA Regulatory Networks Involved in the Tumorigenesis and Development of Adamantinomatous Craniopharyngioma.

Authors:  Dingkang Xu; Yufeng Guo; Shixiong Lei; Abao Guo; Dengpan Song; Qiang Gao; Shengqi Zhao; Kaiwen Yin; Qingjie Wei; Longxiao Zhang; Xiaoxuan Wang; Jie Wang; Qi Zhang; Fuyou Guo
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

6.  Periostin Facilitates the Epithelial-Mesenchymal Transition of Endometrial Epithelial Cells through ILK-Akt Signaling Pathway.

Authors:  Qiao-Mei Zheng; Jing-Jing Lu; Jing Zhao; Xuan Wei; Lu Wang; Pei-Shu Liu
Journal:  Biomed Res Int       Date:  2016-03-13       Impact factor: 3.411

7.  Periostin, a signal transduction intermediate in TGF-β-induced EMT in U-87MG human glioblastoma cells, and its inhibition by anthocyanidins.

Authors:  Amira Ouanouki; Sylvie Lamy; Borhane Annabi
Journal:  Oncotarget       Date:  2018-04-24

8.  Feasibility of primary human cell cultures as a model for adamantinomatous craniopharyngioma research: Evidence from RNA-Seq analysis.

Authors:  Pei-Dong Zhang; Chao-Hu Wang; Jun Fan; Jun-Xiang Peng; Jun Pan; Song-Tao Qi; Yi Liu
Journal:  Oncol Lett       Date:  2020-01-16       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.